A treatment algorithm evaluating the effect of zoledronic acid on bone mineral density loss after allogeneic stem cell transplantation

DOI number 10.58109/f853-wn84
Publisher Australasian Leukaemia and Lymphoma Group (ALLG)

Australasian Leukaemia and Lymphoma Group (ALLG)

Andrew Grigg (Austin Hospital)

Date Made Available 2023
Dataset Individual participant data (IPD) in aggregate form
Description of Dataset

Dataset includes:

  • Data for 82 patients that had undergone bone marrow transplant
  • Trial assessed the use of zoledronic acid as a treatment to reduce bone mineral density loss
  • Dataset includes demographic data, diagnostic, treatment data, outcome data

Australasian Leukaemia and Lymphoma Group (ALLG)

Subject (ANZSRC Category)

Cancer therapy (excl. chemotherapy and radiation therapy)

ANZCTR Reference ACTRN12607000596404
Dataset Access

Access can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with this trial or email enquiries to info@allg.org.au